🇺🇸 FDA
Patent

US 10501740

Compositions and methods for inhibiting expression of factor V

granted A61KA61K47/554A61K48/00

Quick answer

US patent 10501740 (Compositions and methods for inhibiting expression of factor V) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K47/554, A61K48/00, A61P, A61P7/02